Dawn Svoronos

Ms. Svoronos has served as a member of GBT’s board of directors since December 2018. She has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia. Most recently, she served as interim chief commercial officer for Medivation, Inc. Before that, she spent nearly 25 years at Merck & Co., Inc., where she held positions of increasing seniority and leadership, including president of Europe/Canada; vice president of Asia Pacific; and vice president, global marketing, for the Arthritis, Analgesics and Osteoporosis franchise. Earlier in her career, she held positions at Webber Pharmaceuticals and Allergan. Ms. Svoronos sits on the boards of several public companies, including Endocyte and PTC Therapeutics. She received a B.A. in English and French literature from Carleton University in Ottawa, Canada.